FDA Panel BACKS Onyx Pharma and 4 Sizzling Stocks on Trading Radars
Burger King Worldwide Inc. (NYSE:BKW): After it completed a merger with a company which was co-founded by William Ackman, Burger King Worldwide Inc. has advanced in its return to the New York Stock Exchange on Wednesday. Shares of Burger King Worldwide Inc. are trading 2.27% higher today.
Celgene Corporation (NASDAQ:CELG) was issued delays in its attempts to expand its Revlimid label. The company had hoped to gain approval in the EU for the drug as a fron-line maintenance therapy used to treat patients with multiple myeloma, MM, but Celgene has withdrawn its marketing application. Celgene added the new drug application (MDA) for pomalidomide which treats patients with relapsed and refractory MM has been accepted by the FDA. The FDA should announce its final decision by February 10, 2013. Celgen also seeks European approval for pomalidomide. Shares of Celgene Corporation are trading 2.52% higher today.
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX): Late Wednesday, the FDA panel supported Onyx’s Kryprolis, or carfilzomi, intended for patients suffering from relapsed and refractory multiple myeloma who have been through a minimum of two prior forms of therapy. The FDA tends to follow the advice of its panel. Shares of Onyx Pharmaceuticals, Inc. are trading 3.68% higher today.
CarMax, Inc (NYSE:KMX): According to BGB Securities, the reasons for CarMax’s low Q1 results should be temporary, and the sell-off in shares yesterday signifies a buying opportunity for long-term investors. The firm gives a Buy rating and a $37 price target on the stock. Shares of CarMax, Inc are trading .95% lower today.
Bed Bath & Beyond Inc. (NASDAQ:BBBY): Although Bed Bath & Beyond shows a weak outlook, analysts predict that the long-term bull case is intact, says Barron’s. This is based on the class-leading merchandising, execution, square footage growth opportunities, share gains via traffic increases, organic operating margin gain opportunities, and free cash flow generation of the company. According to Raymond James analyst Budd Bugatch, who gives the company a Strong Buy rating, shares could increase about 38% reaching $85. Shares of Bed Bath & Beyond Inc. are trading 0.16% higher today.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.